Global host metabolic response to Plasmodium vivax infection: a 1H NMR based urinary metabonomic study
© Sengupta et al; licensee BioMed Central Ltd. 2011
Received: 24 October 2011
Accepted: 23 December 2011
Published: 23 December 2011
Plasmodium vivax is responsible for the majority of malarial infection in the Indian subcontinent. This species of the parasite is generally believed to cause a relatively benign form of the disease. However, recent reports from different parts of the world indicate that vivax malaria can also have severe manifestation. Host response to the parasite invasion is thought to be an important factor in determining the severity of manifestation. In this paper, attempt was made to determine the host metabolic response associated with P. vivax infection by means of NMR spectroscopy-based metabonomic techniques in an attempt to better understand the disease pathology.
NMR spectroscopy of urine samples from P. vivax- infected patients, healthy individuals and non-malarial fever patients were carried out followed by multivariate statistical analysis. Two data analysis techniques were employed, namely, Principal Component Analysis [PCA] and Orthogonal Projection to Latent Structure Discriminant Analysis [OPLS-DA]. Several NMR signals from the urinary metabolites were further selected for univariate comparison among the classes.
The urine metabolic profiles of P. vivax- infected patients were distinct from those of healthy individuals as well as of non-malarial fever patients. A highly predictive model was constructed from urine profile of malarial and non-malarial fever patients. Several metabolites were found to be varying significantly across these cohorts. Urinary ornithine seems to have the potential to be used as biomarkers of vivax malaria. An increasing trend in pipecolic acid was also observed. The results suggest impairment in the functioning of liver as well as impairment in urea cycle.
The results open up a possibility of non-invasive analysis and diagnosis of P. vivax using urine metabolic profile. Distinct variations in certain metabolites were recorded, and amongst these, ornithine may have the potential of being used as biomarker of malaria. Pipecolic acid also showed increasing trend in the malaria patient compared to the other groups.
KeywordsPlasmodium vivax NMR metabonomics metabolites biomarker
Malaria is caused by parasites of the genus Plasmodium. The five Plasmodium species that are responsible for human malaria are Plasmodium vivax, Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale and Plasmodium knowlesi. Every year, 200-300 million people are affected with malaria with an annual mortality rate of nearly one million . Sub-Saharan Africa and Southeast Asia are some of the most affected regions. In India, P. vivax is the predominant cause of clinical malaria .
Metabonomics is a comparatively recently developed technology defined as the global, dynamic response of living organism towards genetic and environmental perturbations . The technique involves the NMR or mass spectra analysis of biofluids such as urine and serum, etc. followed by multivariate analyses using Principal Component Analysis [PCA] or Orthogonal Partial Least Square - Discriminant Analysis [OPLSDA]. Essentially this provides the clustering of the samples into classes. This also provides the identity of specific NMR/mass spectral signature[s] that are responsible for the clustering/classification. This, in turn, leads to identification of the metabolite[s] that are specifically perturbed in response to the stress factor [genetic or environmental] under investigation . Metabonomics, although a relatively new technology, is being used extensively in pharmacological industry [6, 7]. Metabonomic analysis is also being utilized in identification of novel biomarkers and/or metabolic characterization during different diseases, such as diabetes  and congenital heart disease .
Malaria is an ancient infectious disease that has afflicted humans since pre-historic times. Severity in the clinical malarial disease occurs frequently, and has been well documented for P. falciparum infections [10, 11]. The severity or pathogenicity is likely to be due to metabolic complications arising as a result of host parasite interactions in which the pathogen may divert the host nutrients, and/or release toxic metabolites. Metabolomic analysis will allow a direct read out for such complications. Using axenic cultures, the changes in metabolomic profiles have been documented for the intraerythrocytic stages of P. falciparum[12–14]. However, there have been very few studies on the effects on the metabolic profile of the host during malarial infection. Although body fluids such as urine and plasma are amenable to such metabolomic analysis, very few reports exist of such studies. Urine, as an easily available fluid, is also a very good reporter of the overall metabolic status of the whole organism. Systemic level analysis of host metabolic response towards malaria is delineated only in two rodent model studies. In one of the studies, existence of sexual dimorphism was shown in the alterations of sera, urine and brain metabolic profile in the rodent model of malaria . In another study Nicholson and co-workers delineated the global metabolic response to Plasmodium berghei infection . No metabolomic information exists so far for human patient samples. In particular, very little is known for P. vivax patients, although it has been observed recently that P. vivax can cause high levels of pathological complications [17, 18].
In this report, a NMR based metabonomic approach is delinated to study the urine samples of P. vivax malaria patients and try to correlate the changes observed in them to the known and reported biochemical processes. The paper describes a study of global host metabolic responses towards P. vivax infection. The results ascertain differences in metabolic response in the urinary metabolic profile of the P. vivax infected persons with respect to that of healthy individuals and also with the patients of non-malarial fever. The differential metabolites are delineated, raising the possibility of a non-invasive diagnosis of malaria.
This study was approved by and carried out according to the guidelines of the Local Institutional Ethics Committee. Informed consent was obtained prior to sample collection.
Midstream urine samples (~10 ml) of malaria-infected individuals were collected from local pathological laboratories in sterile tubes containing a final concentration of 0.02% sodium azide. The inclusion criteria followed to recruit the subjects in the study were as follows- (1) Adult males (age ranging from 30 to 50 years), (2) Malaria cohort of those patients that tested positive for P. vivax by blood smear microscopy and (3) Subjects able to consent through informed consent document. Certain exclusion criteria were also followed viz. (1) All females and males < 30 and > 50 years of age, (2) Patients with P. falciparum and mixed P. falciparum/P. vivax infections and (3) Patients with other chronic diseases and/or previous history of any type of malarial infection. In total 53 individuals (all males) were recruited for the study: 21 P. vivax- infected patients, 21 healthy controls and 12 patients with non-malarial fever. Their age ranges were: malaria patients: 35 ± 3.95 years: healthy individuals: 44 ± 3.18 years: and non-malarial fever patients: 40.5 ± 5.33 years (median ± standard error). The samples were transported from the site of collection to the laboratory at 0°C and were immediately processed .
Sample preparation for NMR experiments
An aliquot (800 μL) of collected urine sample was mixed with 400 μL phosphate buffer (an 81:19 (v/v) mixture of 0.2 M Na2HPO4 and 0.2 M NaH2PO4; pH 7.4, made in deionized and 0.22 mm filtered water). This mixture was homogenized and left to stand for 5 min at ambient temperature following which it was centrifuged for 6 min at 6000 g to remove any suspended matter. The clear supernatant (600 μL) was transferred to 5 mm NMR tube (Wilmad, USA) and 50 μL D2O, containing 2, 2-dimethyl-2-silapentane-5-sulfonic acid (DSS) at 0.01% final concentration, was added to it. D2O served as a field-frequency lock and DSS was the internal chemical shift reference. The samples were stored frozen at -20°C until required for NMR experiments.
The NMR spectra were acquired on AVANCE 500 MHz Bruker NMR spectrometer equipped with a 5 mm broad-band inverse probe. The operating frequency on this machine was 500.13 MHz for 1H. For the 1D experiments the spectral width was 12.01 ppm, an excitation pulse of 9 μs (~70°), and a relaxation delay of 1 s between consecutive pulses. This resulted in an acquisition time of 0.68 s and a cycle time of 1.68 s. A total of 64 transients were acquired into 8,192 data points. The water suppression routine involved excitation sculpting using gradients. For processing the FIDs were subjected to exponential multiplication leading to an additional line broadening of 0.20 Hz. A sine bell apodization was also used prior to Fourier transformation. The 1H NMR spectra were manually phase and baseline corrected. For identification of metabolites two dimensional (2D) experiments were performed on selected samples. 2D COSY spectra were acquired with 32 transients in the direct dimension for each of the 256 increments in the indirect dimension. The spectral width was 12.01 in both the dimensions. The pulse width used was 11.80 μs with a delay of 1.5 s. The processing parameters of the data included a QSINE window function, exponential multiplication of 0.20 and 0.30 Hz in the direct and indirect dimension respectively, followed by Fourier transformation in both the dimensions. The 2D TOCSY experiments were performed using similar acquisition parameters. The processing parameters were also identical with an extra Gaussian multiplication of 0.10 Hz prior to Fourier transformation in both the dimensions. The 2D spectra aided in assignment of the NMR resonances to the specific metabolites. In addition, comparison with reported experimental and calculated spectra was done using Human Metabolome Data Base (http://www.hmdb.ca/search/spectra).
Data reduction and analyses
The frequency domain 1H NMR spectra were manually phased and baseline corrected. For data reduction the individual spectrum (0.50 to 9.50 ppm) were divided into frequency bins of width 0.04 ppm each resulting in a total of 191 bins per spectrum. Each bin was integrated using MestReC 4.7.0. In order to avoid the artefacts of water suppression and the variable concentration of urea, the region 4.3 to 6.6 ppm was excluded from the binning procedure. The integrals were normalized to the total intensity of the spectrum to compensate for the inter-sample dilution effects. This was achieved by an algorithm developed in-house. The data was mean-centered (the average value of each bin for all samples was subtracted from individual integrals) and Pareto scaled. The preceding operation resulted in similar weight being given to all the bins and the resultant multivariate models were not dominated by bins representing metabolites high in concentration. Next, the data so generated served as input for PCA and OPLS-DA, which were performed on the SIMCA-P + 12.0 platform (Umetrics, Umea, Sweden).
PCA is an unsupervised pattern recognition technique where no class identity is assigned to the samples a priori. This helps in visualizing any pattern that is present in the data and also identifies the outliers. The class specific segregation can be refined using OPLS-DA. This is a supervised technique where class specificity is assigned towards the sample set a priori. This aided in the visualization of the data as scores plot. In such a plot each point represents a spectrum and the pattern and the segregation in the data can be visualized. This pattern is due to one or more spectral bin(s) which can be visualized using a loadings plot where each point represents a spectral bin. The OPLS-DA model is judged using two parameters. R2X signifies the total explained variation in the data whereas the Q2(cum) explains the extent of separation between the classes as well as the predictability of the model.
Integration of NMR peaks
The spectral bins contributing to the variation seen in the OPLS-DA models (visualized in terms of scores plot) were assigned to specific metabolites as described in the previous section. For further quantification of these metabolites, univariate analysis of the NMR spectral peaks was performed in the following way: the peak of the metabolite contributing to the variation in the OPLS-DA model was assigned in the one-dimensional NMR spectral profiles of the individuals. These peaks were integrated, normalized to the whole region of the spectral profile and compared between the classes concerned using student's t-test to judge the significance in their difference across the classes.
Multivariate statistical analysis
OPLS-DA model bins selected for assignment of metabolites based on differences between patients of vivax malarial and healthy individuals
Bin (Chemical shift)
Variable importance on projection (VIP) values
Increased in urine metabolic profile of P.vivax infected patients
Decreased in urine metabolic profile of P.vivax infected patients
OPLS-DA model bins selected for assignment of metabolites based on differences between patients of vivax malarial and non-malarial fevers
Bin (Chemical shift)
Variable importance values
Decreased in urine metabolic profile of P.vivax infected patients
Increased in urine metabolic profile of P.vivax infected patients
Urinary metabolites perturbed in the Plasmodium vivax - infected patients compared to healthy individuals.
Metabolites increased in P. vivax-infected individuals
Metabolites decreased in P. vivax-infected individuals
P. vivax-infected individuals and healthy controls
N - acetylornithine
biopterin, 3- hydroxybutyrate
N - acetylglutamate
Urinary metabolites perturbed in the Plasmodium vivax- infected patients compared to non-malarial fever patients.
Metabolites increased in P. vivax-infected individuals
Metabolites decreased in P. vivax-infected individuals
P. vivax-infected individuals and patients with non-malarial fever
Integration of spectral peaks and univariate analysis
Several metabolites also showed significant variation across malaria and non-malarial fever patients. Among them, glucose and ornithine were increased in the urine profile of the malaria patients significantly (Figure 8B, D), while a significant decrease in N-butyrate and acetate levels was observed (Figure 8E, F).
Plasmodium vivax malaria is more prevalent than P. falciparum malaria in most parts of India . Infection of P. vivax is historically believed to be a benign form of malaria. However recent reports suggest that P. vivax can also result in several complications including multiple organ failure, acute respiratory distress syndrome and CNS related problems [21–23]. It is, therefore, becoming even more important to understand the host-parasite interaction for vivax malaria, specifically how the host metabolism responds to the parasite infection. In this paper, a 1H NMR approach is described to understand this process. Urine metabolic profiles of P. vivax- infected individuals, healthy individuals, and patients with non-malarial fever were compared in order to get the malaria specific signatures.
Metabolic syndromes like lactic acidosis due to enhanced glycolysis are known complications during severe malaria [15, 24]. However, enhancement in excretion of lactic acid was not observed in vivax-infected patients. This might be due to low parasitaemia (ranging from 0.01%-0.1%), resulting in insignificant perturbation of glucose metabolism. However, a range of other metabolites were found, which differentiate between the malarial patients and the two control categories.
The urine of malaria patients contained significantly increased amounts of valerylglycine and phenylpyruvic acid compared to that of healthy individuals (Figure 7A, E). However, the level of valerylglycine was not significantly different between the malarial patients and non-malarial fever patients (Figure 9G). Valerylglycine is a minor metabolite in fatty acid break down. The elevation of the urinary acylglycines is an indication of impaired β-oxidation of fatty acid . Therefore, it may be concluded that the impairment in fatty acid β-oxidation is associated with febrile condition.
Data presented here also indicates a disturbance in the phenylalanine metabolism. Phenylalanine is known to be metabolized by phenylalaninehydroxylase and tetrahydrobiopterin (THBP) to tyrosine. Alteration of this pathway leads to the formation of phenylpyruvate. Usually phenylpyruvate is a minor metabolite of phenylalanine. However, in patients with phenylketonuria, the phenylalanine-tyrosine pathway is blocked leading to excess formation of phenylpyruvate . A significantly enhanced excretion of phenylpyruvic acid in the malarial patients compared to healthy individuals was observed in our experiments (Figure 7E). This 'phenylketonuric condition' is probably arising out of an impaired phenylalanine metabolism. The data also suggests a possible increase in the biopterin concentration in the urine of malaria patients (Figure 7F). Some atypical form of phenylketonuria has been characterized by an increase in the urinary biopterin, which is caused by malfunction of dihydropteridinereductase (DHPR) . Hyperphenylalaninemia is associated with severe P. falciparum malaria in African children . However, this does not seem to be the case in the present study as the phenylpyruvic acid excretion is not significantly different between the malaria and non-malarial fever patients (Figure 9E). Although, the overlapped peaks of phenylalanine and hippurate showed a significant increase in the urine of malaria patients compared to that of non-malarial fever patients (Figure 8A), this cannot be taken to an indication of hyperphenylalaninemia. The hyperphenylalaninemic condition may be an associated complication of fever. However, there seems to be no study that deals with the metabolite profiling during fever in humans, therefore it remains an interesting aspect to be investigated.
Ornithine is a part of the urea cycle. In the first step of the cycle, ornithinecarbamoyltransferase (OCT) acts on ornithine and carbamoylphosphate to begin the natural detoxification of ammonia. Earlier reports suggested that elevation of serum value of OCT can be a potential marker of malaria and this was associated with the damage of the liver cells in the liver stage of the parasite [27, 28].
Perturbation of OCT levels are likely to result in an impaired urea cycle. Urea cycle is the major pathway for ammonia detoxification in mammals. Earlier reports indicated ammonia toxicity during malaria in mice model . Observation of significant increase in the urinary level of both ornithine (Figure 8D) and N-acetylornithine (Figure 9A) in malaria patients (compared to non-malarial fever patients) and an increased level of N-aceylornithine (compared to healthy individuals) (Figure 7B) also points to possible hepatic injury and impaired urea cycle resulting in ammonia toxicity during P. vivax infection. In the light of results presented here, earlier reports of statistically significant decrease of ornithine in the plasma of patients with clinical malaria  may be interpreted as an enhanced excretion of ornithine in malaria patients.
Pipecolic acid is a minor metabolite of lysine catabolism. In humans, pipecolic acid is found to be associated with chronic liver disease, pyridoxine dependent epilepsy and Zellweger syndrome [30–32]. Recent studies in the murine malaria model show elevated pipecolic acid level in the urine of NMRI mice . Liver dysfunction is associated with malaria. However, the cause for the elevated pipecolic acid during malaria remains unclear. Although statistically not very significant, this metabolite was present in larger quantities in the urine of malarial patients compared with non-malarial fever patients (Figure 9D). Earlier studies showed hyperlysinaemia in the sera of P. berghei ANKA infected mice . Hyperlysinaemia is often related to activation of minor metabolic pathway hence an enhanced pipecolic acid excretion . From the data reported here and earlier data from murine malaria model it seems likely that lysine metabolism is perturbed during the course of malarial infection. However, the underlying biochemical reason remains to be addressed.
The non-malarial fever category serves as a control for general fever related changes that are not specific to P. vivax infection. Febrile illnesses are often likely to be misdiagnosed as malaria. Lundqvist and co-workers showed that borreliosis can be misdiagnosed as malaria due to the similarity in the symptoms . Poorly executed microscopy also sometimes adds on to this, leading to malaria overdiagnosis and overuse of anti-malarial in malaria endemic regions [35, 36]. In this report, it is shown that the non-malarial fevers can be separated from vivax patients on the basis of the urinary metabolite profile of the patients. The urine metabolomic profile seems to be significantly different in these two categories (Figures 3 and 4). This is due to the difference in the levels of Phenylalanine, hippurate, glucose, glutamine, alanine, and ornithine which are increased in the urine of the P. vivax-infected individuals and n-butyrate and acetate which are decreased in these patients (Figure 8, Table 4). Pipecolic acid also showed a higher trend in the urine of malaria patients compared to non-malarial fever patients (Figure 9D). As is evident from a very high Q2(cum) which is equal to 0.89 from the OPLS-DA model made from the urinary metabolite profile of the non-malarial fever patients and P. vivax- infected individuals, urinary metabolic profiles have a potential to be of diagnostic use for detecting malaria and to differentiate malaria from other non-malarial fevers.
This study reports on the understanding of the host metabolic changes in terms of the urinary metabolite profile of the P. vivax- infected patients. Urinary metabolite profile of malaria patients were found to be distinct from both healthy individuals and those of non-malarial fever patients. Among several changes in metabolism, a disruption in the urea cycle in terms of ornithine excretion was noted, along with an elevated level of pipecolic acid indicating possible hepatic injury. Ornithine, therefore, promises to be candidate biomarker for malarial infection. Moreover, an extremely predictive model was constructed from urinary metabolite profile of the clinical malaria patients and individuals with non-malarial fever. This might help in the non-invasive diagnosis of malarial infection. Malaria-specific signatures were observed in the urine and showed that the urine profile of malaria patients cluster separately from different groups of control populations in spite of the high variability of urine metabolites across individuals. This study, therefore opens up the possibility of finding out malaria specific biomarkers in the urine, which might help in non invasive diagnosis of the infection in the long run. Many parameters, such as genetic make up, food habits and lifestyle, may influence urine metabolite patterns. In order to circumvent such confounding parameters, a longitudinal follow up and comparison of urine from cohorts of malaria patients and other control subjects will provide further specific information regarding disease related changes in patients of P. vivax malaria.
The authors are grateful to the National Facility for High-field NMR, TIFR and Dr R.Y. Agarkar of TIFR Medical section for all their help. We thank Dr S. Bhayani and Dr A. Mehta for help in sample collection. AS thanks the Council of Scientific and Industrial Research, Govt. of India for the Shyama Prasad Mukherjee Fellowship.
- Trampuz A, Jereb M, Muzlovic I, Prabhu R: Clinical review: Severe malaria. Crit Care. 2003, 7: 315-323. 10.1186/cc2183.PubMed CentralView ArticlePubMed
- Wim Van Lerberghe TE, Kumanan R, Abdelhay M: World Malaria Report. World Malaria Report (Editor eds.). 2008, World Health Organization
- Joshi H, Prajapati KS, Verma A, Kang'a S, Carlton JM: Plasmodium vivax in India. Trends Parasitol. 2008, 24: 228-235. 10.1016/j.pt.2008.01.007.View ArticlePubMed
- Nicholson JK, Lindon JC: Systems biology: metabonomics. Nature. 2008, 455: 1054-1056. 10.1038/4551054a.View ArticlePubMed
- Lindon JC, Holmes E, Nicholson JK: Pattern recognition methods and applications in biomedical magnetic resonance. Prog NMR Spec. 2001, 39: 1-40. 10.1016/S0079-6565(00)00036-4.View Article
- Lindon J, Holmes E, Nicholson J: Metabonomics techniques and applications to pharmaceutical research & development. Pharma Res. 2006, 23: 1075-88. 10.1007/s11095-006-0025-z.View Article
- Robertson DG, Reily MD, Cantor GH, John CL, Jeremy KN, Elaine H: Metabonomics in preclinical pharmaceutical discovery and development. The Handbook of Metabonomics and Metabolomics. 2007, Amsterdam: Elsevier Science B.V, 241-277.View Article
- Yuan K, Kong H, Guan Y, Yang J, Xu G: A GC-based metabonomics investigation of type 2 diabetes by organic acids metabolic profile. Journal Chroma B. 2007, 850: 236-240. 10.1016/j.jchromb.2006.11.035.View Article
- Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, Bethell HWL, Clarke S, Schofield PM, McKiligin E, Mosedale DE, Grainger DJ: Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med. 2002, 8: 1439-1445. 10.1038/nm1202-802.View ArticlePubMed
- Planche T, Dzeing A, Nqou-Milama E, Kombila M, Stackpole PW: Metabolic complications of severe malaria. Curr Top Microbiol Immunol. 2005, 295: 105-136. 10.1007/3-540-29088-5_5.PubMed
- Mackintosh CL, Beeson JG, Marsh K: Clinical Features and pathogenesis of severe malaria. Trends Parasitol. 2004, 20: 597-603. 10.1016/j.pt.2004.09.006.View ArticlePubMed
- Olszewski KL, Morrisey JM, Wilinski D, Burns JM, Vaidya AB, Rabinowitz JD, Llinas M: Host parasite interaction revealed by Plasmodium falciparum Metabolomics. Cel Host Microb. 2009, 5: 191-199. 10.1016/j.chom.2009.01.004.View Article
- Plata G, Hsiao TL, Olszewski KL, Llinas M, Vitkup D: Reconstruction and Flux- balance analysis of the Plasmodium falciparum metabolic network. Mol Syst Biol. 2010, 6: 408-422.PubMed CentralView ArticlePubMed
- Teng R, Junankar PR, Bubb WA, Rae C, Kirk K: Metabolite profiling of the intraerythrocytic malaria parasite Plasmodium falciparum. NMR Biomed. 2009, 22: 292-302. 10.1002/nbm.1323.View ArticlePubMed
- Basant A, Rege M, Sharma S, Sonawat HM: Alterations in urine, serum and brain metabolomic profiles exhibit sexual dimorphism during malaria disease progression. Malar J. 2010, 9: 110-10.1186/1475-2875-9-110.PubMed CentralView ArticlePubMed
- Li JV, Wang Y, Saric J, Nicholson JK, Dirnhofer S, Singer BH, Tanner M, Wittlin S, Holmes E, Utzinger JR: Global metabolic responses of NMRI mice to an experimental Plasmodium berghei infection. J Prot Res. 2008, 7: 3948-3956. 10.1021/pr800209d.View Article
- Rogerson SJ, Carter R: Severe vivax malaria: newly recognised or rediscovered?. PLoS Med. 2008, 5: 875-877.View Article
- Kochar DK, Das A, Kochar SK, Saxena V, Sirohi P, Garg S, Kochar A, Khatri MP, Gupta V: Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in Northwestern India. Am J Trop Med Hyg. 2009, 80: 194-198.PubMed
- Lauridsen M, Hansen SH, Jaroszewski JW, Cornett C: Human urine as test material in 1H NMR-based metabonomics: recommendations for sample preparation and storage. Anal Chem. 2007, 79: 1181-1186. 10.1021/ac061354x.View ArticlePubMed
- Sengupta A, Ghosh S, Sonawat HM, Basant A, Sharma S, Kshirsagar NA, Gogtay N: A urine 1H NMR based metabonomic approach to understand the host metabolic response towards plasmodium vivax infection. Proceedings of International Conference on Systems in Medicine and Biology: 16-18 December 2010. Edited by: Manjunatha M. 2010, Kharagpur, 172-176. IEEEView Article
- Anvikar A, Singh D, Singh R, Dash A, Valecha N: Vivax malaria presenting with cerebral malaria and convulsions. Acta Parasitol. 2010, 55: 96-98. 10.2478/s11686-010-0013-7.View Article
- Koibuchi T, Nakamura T, Miura T, Endo T, Nakamura H, Takashi T, Kim HS, Watawa Y, Washizaki K, Yoshikawa K: Acute disseminated encephalomyelitis following Plasmodium vivax malaria. J Infect Chemo. 2003, 9: 254-256. 10.1007/s10156-003-0244-8.View Article
- Beg MA, Khan R, Baig SM, Gulzar Z, Hussain R, Smego Ra: Cerebral involvement in benign tertian malaria. Am J Trop Med Hyg. 2002, 67: 230-232.PubMed
- Mehta M, Sonawat HM, Sharma S: Malaria parasite-infected erythrocytes inhibit glucose utilization in uninfected red cells. FEBS Letters. 2005, 579: 6151-6158. 10.1016/j.febslet.2005.09.088.View ArticlePubMed
- Kimura M, Yamaguchi S: Screening for fatty acid beta oxidation disorders: Acylglycine analysis by electron impact ionization gas chromatography-mass spectrometry. J Chrom B: Biomed Sci Appl. 1999, 731: 105-110. 10.1016/S0378-4347(99)00208-X.View Article
- Jon CN, Ching-Lun L, Sheldon M, Seymour K, Klaus B: Neopterin and biopterin levels in patients with atypical forms of phenylketonuria. J Neurochem. 1980, 35: 898-904. 10.1111/j.1471-4159.1980.tb07088.x.View Article
- Lopansri BK, Anstey NM, Stoddard GJ, Mwaikambo ED, Boutlis CS, Tjitra E, Maniboey H, Hobbs MR, Levesque MC, Weinberg JB, Granger DL: Elevated plasma phenylalanine in severe malaria and implications for pathophysiology of neurological complications. Infect Immun. 2006, 74: 3355-3359. 10.1128/IAI.02106-05.PubMed CentralView ArticlePubMed
- Sampath SLS, Somani BL, Sharma YV, Arora MM, Ambade VN: Serum Ornithine carbamoyl transferase as a surrogate marker in malaria. Med J AFI. 2002, 58: 315-8.
- Penet MF, Kober F, Confort-Gouny S, Fur YL, Dalmasso C, Coltel N, Liprandi A, Gulian JM, Grau GE, Cozzone PJ, Viola A: Magnetic resonance spectroscopy reveals an impaired brain metabolic profile in mice resistant to cerebral malaria infected with Plasmodium berghei ANKA. J Biol Chem. 2007, 282: 14505-14514. 10.1074/jbc.M608035200.View ArticlePubMed
- David MD, Patricia T, Caroline A, Peter C: Cerebro-hepato-renal syndrome of Zellweger: a report of eight cases with comments upon the incidence, the liver lesion, and a fault in pipecolic acid metabolism. J Pediatrics. 1975, 86: 382-387. 10.1016/S0022-3476(75)80967-X.View Article
- Hironaka K, Tatsuaki H, Masako N, Kenzo T: Plasma levels of pipecolic acid in patients with chronic liver disease. Hepatology. 1988, 8: 286-289. 10.1002/hep.1840080216.View Article
- Barbara P, Sylvia S-I, Eduard P, Wolfgang E, Eduard AS, Cornelis J: Pipecolic acid elevation in plasma and cerebrospinal fluid of two patients with pyridoxine-dependent epilepsy. Ann Neurol. 2000, 48: 121-125. 10.1002/1531-8249(200007)48:1<121::AID-ANA20>3.0.CO;2-V.View Article
- Dancis J, Hutzler J, Cox RP: Familial hyperlysinemia with lysine ketoglutarate- reductase insufficiency. J Clin Invest. 1969, 48: 1447-52. 10.1172/JCI106110.PubMed CentralView ArticlePubMed
- Lundqvist J, Larsson C, Nelson M, Andersson M, Bergstrom S, Persson C: Concomitant infection decreases the malaria burden but escalates relapsing fever borreliosis. Infect Immun. 2010, 78: 1924-30. 10.1128/IAI.01082-09.PubMed CentralView ArticlePubMed
- Shillcutt SD, Morel CM, Coleman PG, Mills AJ, Goodman CA: Cost-effectiveness of malaria diagnosis in sub-Saharan Africa: the role of rapid diagnostic tests in rural settings with high Plasmodium falciparum transmission. A report for WHO-UNICEF-UNDP-World Bank Special Programme for Research and Training in Tropical Diseases (TDR). 2006
- Elhassan EM, Haggaz AED, Magzoub MM, Adam I: Non-malarial fever among pregnant women in Medani Hospital, Sudan: diagnostic uncertainty and overtreatment with quinine. Asian Pacific J Trop Med. 2010, 3: 392-394. 10.1016/S1995-7645(10)60095-8.View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.